Effects of subjective symptoms and quality of life by the adherence with anti-histamine ophthalmic solution in patients with seasonal allergic conjunctivitis - A multicenter, prospective, cross-sectional study -

Effects of subjective symptoms and quality of life by the adherence with anti-histamine ophthalmic solution in patients with seasonal allergic conjunctivitis - A multicenter, prospective, cross-sectional study - - Cross-sectional study about the adherence with anti-histamine ophthalmic solution in patients with seasonal allergic conjunctivitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039554

Enrollment

800

Registered

2020-02-25

Start date

2020-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seasonal allergic conjunctivitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient diagnosed with seasonal allergic conjunctivitis in spring before 2019 Patient who has been prescribed anti-histamine ophthalmic solution on the day of informed consent.

Exclusion criteria

Exclusion criteria: Patient with severe allergic conjunctival disease (VKC, atopic keratoconjunctivitis) Patient who received treatment before pollen dispersal for seasonal allergic conjunctivitis after the end of 2019

Design outcomes

Primary

Measure	Time frame
Effect of subjective symptoms and QOL with ophthalmic solutions adherence status	—

Countries

Japan

Contacts

Public ContactHirotsugu Kishimoto

Santen Pharmaceutical Co., Ltd. Japan Medical Affairs, Development Management Department, Japan Business

clinical@santen.co.jp06-4802-9603

Outcome results